Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Brand: Mavenclad®
NICE TA: 493
Indication: Treating relapsing–remitting multiple sclerosis (NICE TA493)
Disease category: Immune system and Malignant Disease
Commissioning responsibility: NHS England
PbR excluded: Yes


Cladribine tablets are recommended as an option for treating highly active multiple sclerosis in adults, only if the person has:

• rapidly evolving severe relapsing–remitting multiple sclerosis, that is, at least 2 relapses in the previous year and at least 1 T1 gadolinium-enhancing lesion at baseline MRI or

• relapsing–remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as 1 relapse in the previous year and MRI evidence of disease activity.

This recommendation is not intended to affect treatment with cladribine tablets that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.


LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA493 - Cladribine tablets for treating relapsing–remitting multiple sclerosis

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG